论文部分内容阅读
[目的]分析不同级别宫颈癌前病变及宫颈癌中错配修复基因hMLH1和hMSH2蛋白表达情况。[方法]收集宫颈活检及手术标本139例,其中宫颈上皮内瘤变(CIN)Ⅰ级43例,CINⅡ、Ⅲ级48例,宫颈鳞癌(SCC)48例;对照组慢性宫颈炎50例。用免疫组化技术检测hMLH1和hMSH2蛋白,分析其与宫颈病变级别及宫颈癌临床病理特征关系。[结果]hMLH1阳性率在CIN各组明显高于慢性宫颈炎及SCC组,差异有统计学意义(P<0.01)。hMSH2阳性率随宫颈病变级别增加而升高,差异有统计学意义(P<0.01);但SCC组与CIN各组相比差异无统计学意义。hMLH1阳性率随FIGO分期增加而下降,但差异无统计学意义;hMSH2阳性率随FIGO分期增加而上升,且与淋巴转移及病理分级有关(P<0.05)。两者与肿瘤大小均无关。[结论]错配修复基因hMLH1、hMSH2蛋白与宫颈癌发生发展有关,但两者作用机制可能不同。
[Objective] To analyze the expression of mismatch repair genes hMLH1 and hMSH2 in different grades of cervical precancerous lesions and cervical cancer. [Methods] 139 cases of cervical biopsy and surgical specimens were collected, including 43 cases of grade Ⅰ cervical intraepithelial neoplasia (CIN), 48 cases of CINⅡ, Ⅲ grade 48 cases, 48 cases of cervical squamous cell carcinoma (SCC) and 50 cases of chronic cervicitis in control group. Immunohistochemical detection of hMLH1 and hMSH2 protein, cervical lesions and cervical lesions and clinicopathological features. [Results] The positive rate of hMLH1 in CIN groups was significantly higher than that in chronic cervicitis and SCC groups (P <0.01). The positive rate of hMSH2 increased with the increase of cervical lesions, the difference was statistically significant (P <0.01). However, there was no significant difference between SCC and CIN groups. The positive rate of hMLH1 decreased with the increase of FIGO staging, but the difference was not statistically significant. The positive rate of hMSH2 increased with the increase of FIGO staging, and was associated with lymph node metastasis and pathological grade (P <0.05). Both have nothing to do with tumor size. [Conclusion] The mismatch repair genes hMLH1 and hMSH2 are related to the occurrence and development of cervical cancer, but the mechanism may be different.